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Background: The risk of death is significantly higher in TB/HIV-infected patients than in
those patients with just one disease or the other. This study aims to evaluate the impact
of demographic, clinical and laboratory characteristics on the treatment outcome and mor-
tality of TB/HIV co-infected patients in a TB tertiary center in Iran.
Materials and methods: The study was conducted at Iran’s National Referral Center for Tuber-
culosis. In total, 111patientswere recruitedbetween2004and2007.Mycobacteriology studies
were performed for all patients. Demographic, clinical, and lab data of all patients were ana-
lyzed, and predictors of unsuccessful outcomes, as well as mortality, were determined.
Results: The mean age for all 111 TB/HIV patients was 38 ± 9 years (range 22–70) and 107
patients (96.3%) were male; 104 patients (93.7%) had a history of drug abuse, and 96 patients
(86.4%)hadahistoryof imprisonment.The routeof transmissionofHIVwas intravenousdrug
use in 88 of the patients (79.3%); 23 patients (20.7%) had a history of Category 1 (CAT-1) (5.4%)
and CAT-2 treatment. Highly Active Antiretroviral Therapy (HAART) was given to 48 patients
(43.2%). Therewas no significant association found between treatment outcome ormortality
with sex, smoking, drug and alcohol abuse, imprisonment, route of transmission, history of
CAT-1 and CAT-2, cluster of differentiation 4 (CD4), and adverse effects (p > 0.05). Administra-
tion of HAART led to a significantly higher rate of good outcome (p < 0.001). Lower Albumin
levels and body weight were significantly associated with mortality.
Conclusion: Albumin levels andweightcanbepredictorsofmortalityandanunsuccessful out-
come. Administration of HAART led to a better outcome.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Infection by Human Immunodeficiency Virus (HIV) kills more
than 8000 people daily, while more than 5000 people die of
tuberculosis (TB) every day. It is estimated that one third of
the world’s population are infected with TB, and this is conse--African Society for Myco
ari Hospital, Darabad, Nia
arsi).quently true for about 40 million people currently diagnosed
with HIV/AIDS. In addition, without the proper treatment,
90% of the HIV-positive patients will die within months of
contracting TB. Four million people affected with HIV also
have TB worldwide making TB the main killer in HIV-infected
patients [1]. The risk of death is significantly higher in thebacteriology. All rights reserved.
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tive and responds well to anti-TB medications [2–6].
As well, some mortality risk factors have been proposed
among TB/HIV patients [7,8]. However, in this regard, there
remain controversies which are mainly owing to different
settings in various regions, the major route of acquisition, di-
verse demographic characteristics among HIV-positive cases
and dissimilar epidemiologic patterns of infections of TB
and HIV [7–12].
Similar to its global trend [13], the number of HIV-infected
patients in Iran is escalating with many of them being co-in-
fected with TB [14,15].
This study aims to evaluate the impact of demographic,
clinical and laboratory characteristics on the treatment out-
come and mortality of TB/HIV co-infected patients along with
identifying risk factors affecting mortality to determine
whether or not to continue with the available treatment
methods in a TB tertiary center in Iran.
Materials and methods
All National Research Institute of Tuberculosis and Lung Dis-
ease (NRITLD) TB/HIV patients were studied who have been
hospitalized at Masih Daneshvari Hospital, Tehran-Iran, at
the National Referral Center for Tuberculosis between 2004
and 2007. The study comprised a total of 117 patients; 111
of them have completed follow-up procedures. For this pur-
pose, retrospectively, data was extracted from the patients’
medical records.
For all patients, TB and HIV confirmation was under-
taken. Primarily, sputum samples (smear, culture) were col-
lected, chest X-rays were undertaken, and patients were
tested for HIV antibodies; in the case of positive results,
Western Blot testing was done. After initial confirmation
for TB/HIV, first-line drug-susceptibility tests (DST) were
performed for all culture-positive cases. TB treatment was
initiated in accordance with standard CAT-1 regimens. Until
the year 2005, the Iranian national guidelines for manage-
ment of TB among HIV-infected patients consisted of the
initiation of HAART eight weeks after the start of TB treat-
ment if their CD4+ count was less than 200 cells/ml. In or-
der to prevent adverse drug interactions in HIV-infected
patients receiving the HAART treatment, Rifampin was re-
placed with Rifabutin in their TB treatment. However, in
2005 and thereafter, the protocol was updated by adminis-
tering HAART concurrently with TB treatment for patients
with a CD4+ < 100 cells/ml. The new regimen consisted of
Ziduvudin, Lamivudine and Efavirenz, which allowed the
administration of Rifampin as well.
Once DST results were acquired, treatment was modified
accordingly. It should be noted that all patients received
Cotrimoxazole (trimethoprim/sulfamethoxazole) for CD4+ <
200 cells/ml and Azithromycin for CD4+ < 50 cells/ml as pro-
phylaxis against opportunistic infections such as Pneumocystis
carinii pneumonia (PCP) and Mycobacterium avium complex
(MAC), respectively.
Monthly checkups were undertaken for follow-up until the
completion of the treatment. TB treatment outcomes were
measured in accordance with standard definitions.Statistical analysis
For statistical analysis, SPSS software V.15.1 (Apache Software
Foundation, Chicago, Illinois) was used. Continuous variables
were expressed as group means ± SD. Categorical data, such
as ethnicity, were expressed as group frequency and propor-
tion. Statistics without Yates’ correction, Fisher’s exact test,
Student’s t-test and the Mann–Whitney U test were used as
appropriate. All reported p-values are two-sided. A p-value
of less than 0.05 was considered statistically significant.
The protocol of the study was reviewed and approved by
the Scientific and Ethics Committee of the NRITLD.
Results
Totally, the mean age for all 111 TB/HIV patients was
38 ± 9 years (range 22–70), and 107 patients (96.3%) were male.
Smokers accounted for 108 (97.3%) of the patients, 104 of the
patients (93.7%) had a history of drug abuse, 53 patients
(47.7%) were alcohol abusers, and 96 patients (86.4%) had a
history of imprisonment. The method of transmission of
HIV was heterosexual in 11 patients (9.9%), intravenous drug
use in 88 patients (79.3%), homosexual in 1 patient (0.9%), and
transfusion in 9 patients (8.1%). Pulmonary TB cases ac-
counted for 79 (71.2%) patients, while 8 patients (7.2%) had ex-
tra-pulmonary TB, and simultaneous pulmonary and extra-
pulmonary TB was present in 24 (21.6%) patients; 23 patients
(20.7%) had a history of CAT-1 treatment and 6 patients (5.4%)
had received CAT-2 treatment. HAARTwas given to 48 (43.2%)
patients.
Outcomes were classified into two categories: good out-
come and bad outcome. Good outcomes were assigned to all
patients who either were cured or had completed treatment,
and bad outcomes included the patients in whom the treat-
ment led to death, failure, or default (Table 1). Death ac-
counted for 21 (18.9%) patients (Table 2).
Having performed a univariate analysis, a significant asso-
ciation was not found among treatment outcome and sex,
smoking, drug and alcohol abuse, history of imprisonment,
and route of transmission (p > 0.05). In addition, history of
CAT-1 and CAT-2 treatment were not associated with outcome
(p > 0.05). HAART was started only for patients whose CD4
count was less than 200. Surprisingly, administration of
HAART led to a significantly higher rate of good outcomes
in these patients (p < 0.001, CI 95% = 2.1–12.8, OR = 5.2). The
mean CD4 count was 175.8 and 140.09 in patients with good
outcomes and bad outcomes, respectively. Nonetheless, a cor-
relation was not found between the CD4 count and outcome
(p > 0.05). Furthermore, a CD4 count above 100 and below
100 did not affect treatment outcome.
Although the study did not find an association between
weight and outcome, albumin levels were significantly lower
in patients with a bad outcome (p = 0.003; 3.03 ± 0.52 vs.
2.67 ± 0.45). During the course of treatment, 33 (29.7%) pa-
tients developed adverse effects due to either anti-TB or
HAART medications. However, these adverse effects did not
influence the ultimate outcome of the patients (p > 0.05).
All the aforementioned variables were also analyzed
against mortality; however, only age (p = 0.02) and albumin le-
Table 1 – Patients’ characteristics with regard to their final treatment outcome.
Outcome
Good outcome Bad outcome Total
Number Percentage Number Percentage Number Percentage
Gender
Male 69 97.20 38 95 107 96.40
Female 2 2.80 2 5 4 3.60
Route of transmission*
Heterosexual 7 10 4 10.30 11 10.10
IVDU 59 84.30 29 74.40 88 80.70
Homosexual 1 1.40 0 0 1 0.90
Transfusion 3 4.30 6 15.40 9 8.30
Smoker
Yes 70 98.60 38 95 108 97.30
No 1 1.40 2 5 3 2.70
Drug abuse
Yes 67 94.40 37 95.20 104 93.70
No 4 5.60 3 7.50 7 6.30
Alcohol abuse*
Yes 35 50 18 42.9 53 47.7
No 35 50 24 57.1 58 52.3
Prison*
Yes 59 85.50 37 95.20 96 88.10
No 10 14.50 3 7.50 13 11.90
History of CAT-1
Yes 15 21.40 8 19.6 23 20.70
No 55 78.60 33 80.4 88 79.30
History of CAT-2
Yes 4 5.60 2 5 6 5.40
No 67 94.4 38 95 105 94.60
HAART
Yes 40 56.30 8 20 48 43.20
No 31 43.70 32 80 63 56.80
CD4+*
<200 49 71 24 72.7 73 71.6
P200 20 29 9 27.3 29 28.4
Adverse effects
Yes 24 33.80 10 25 34 29.70
No 47 66.20 30 75 77 70.30
* The values were not available as the factor’s status was unknown for some cases.
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mortality. The mean age of patients with mortality was lower
than that of patients without mortality (48.6 ± 9 vs. 54.9 ±
10.8 years). Similarly, albumin levels were lower in patients who
died than in those who survived (2.59 ± 0.45 vs. 2.99 ± 0.51).
Discussion
It is now recognized that both TB and HIV contribute to each
other’s progress [9,16–18]. Patients co-infected with TB and
HIV have higher mortality rates in comparison with those in-
fected with one or the other [2–6,15,19]. In several case series,
the main predictor for survival was the prompt initiation of
effective anti-tuberculosis treatment, HAART administration,
CD4 count, site of the disease, and other previous orconcurrent opportunistic infections caused by immunosup-
pression [7–9,20,21].
All patients were followed throughout their treatment
accordingly; totally, 71 (64%) of the patients reached a suc-
cessful outcome, whereas the same treatment led to an
unsuccessful outcome in 41 (36%) others. In addition, 21 pa-
tients (18.9%) died during the course of treatment. For those
who died, the time interval between treatment initiation
and death was taken into consideration. A median was then
calculated. (Median = 2.50 months, IQR 25–75% = 1.25–8.50,
Range = 0.30–18.00.)
As the data tables and statistical analyses illustrate, a suc-
cessful outcome is associated with having received HAART
treatment and higher albumin levels. Furthermore, the anal-
ysis of mortality in TB/HIV patients is associated with higher
Table 2 – Patients’ characteristics with regard to mortality.
Mortality
Yes No Total
Number Percentage Number Percentage Number Percentage
Gender
Male 19 90.50 88 97.70 107 96.30
Female 2 9.50 2 2.30 4 3.70
Route of transmission*
Heterosexual 2 9.50 9 10.2 11 9.90
IVDU 16 76.20 72 81.8 88 79.30
Homosexual 0 0 1 1.1 1 0.90
Transfusion 3 14.30 6 6.9 9 8.10
Smoker
Yes 19 90.50 89 99.10 108 97.30
No 2 9.50 1 0.90 3 2.70
Drug abuse
Yes 19 90.50 85 95.50 104 93.70
No 2 9.50 5 4.50 7 6.30
Alcohol abuse
Yes 12 57.10 41 45.60 53 47.70
No 9 42.90 49 54.40 58 52.30
Prison
Yes 19 90.50 79 87.70 98 88.30
No 2 9.50 11 12.30 13 11.70
Type
Pulmonary 13 61.90 66 73.30 79 71.20
Extra-Pulmonary 0 0 8 8.80 8 7.20
Both 8 28.10 16 17.90 24 21.60
History of CAT-1
Yes 2 9.5 21 23.30 23 20.70
No 19 91.5 69 76.70 88 79.30
History of CAT-2
Yes 1 4.80 5 5.50 6 5.40
No 20 95.20 85 94.50 105 94.60
HAART
Yes 6 28.60 42 46.70 48 43.20
No 15 71.40 48 53.30 63 46.80
CD4+*
<200 16 84.20 58 70 74 72.50
P200 3 15.80 25 30 28 27.5
Adverse effects
Yes 7 33.30 27 30 34 30.70
No 14 66.70 63 70 77 69.30
* The values were not available as the factor’s status was unknown for some cases.
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information, mortality has no significant association with
receiving HAART treatment. However, this may be owing to
the evidence that those who died experienced a very short
time interval between their time of admission to the hospital
and death. Therefore, there was no opportunity for receiving
an efficacious HAART treatment. This is supported by the fact
that those who had the opportunity to receive HAART showed
an increasingly better response to TB treatment, and their
outcome significantly improved.
Furthermore, the significant association between albumin
levels and treatment outcome and mortality can be rational-
ized as those who had more developed disease, morerecurrent opportunistic infections and more severe malnour-
ishments had lower weight or albumin levels, and hence were
more liable to have anti-TB treatment failure or to die. This
may support the fact that a thorough combat against TB-
HIV co-infection not only requires a well-administered treat-
ment plan for both infections, but also mandates the pres-
ence of a relatively competent immune system, which may
be adversely affected by malnutrition.
Despite the many factors affecting the risk of mortality in
TB/HIV patients, such as the site of culture-proven TB at pre-
sentation, the history of previous opportunistic infection, his-
tory of treatment for tuberculosis, etc., not many studies have
been done on this topic.
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such as albumin or weight as predictors of mortality or a
unsuccessful outcome in TB/HIV patients.
This study denotes that TB/HIV cases presenting to the
center were mostly male IV drug users. As well, most of the
cases (88.1%) have been or are currently imprisoned. This
confirms and emphasizes the importance of implementing
efficient plans for preventing, screening, and treating TB/
HIV in high risk groups such as IV drug users or prisoners,
in whom there is increased risk of contracting both TB and
HIV owing to close contact and more high-risk behaviors.
The purpose of this study consisted of providing standard
care for all patients and administering HAART and TB treat-
ments with a uniform protocol. All eligible patients received
co-Trimoxazole/Azithromycin as prophylaxis against oppor-
tunistic disease. This helps with interpreting the findings
with a more direct relation to the outcomes and mortality.
Of course, this study had several limitations as well. The first
was that the center is a national referral center, which means
that not all acquired data is necessarily a representation of
the entire Iranian society. Secondly, the main pattern of the
transmission route of HIV, as is seen throughout the country,
is intravenous-drug abuse, and the majority of the patients
were male. This may confine the researchers from consider-
ing the obtained results as the exact representative of the Ira-
nian population.
However, it seems that, with regard to the health concern
prompted by increasing TB-HIV infections, it is crucial to con-
duct more comprehensive studies on this issue; particularly
on the predictors and risk factors for unfavorable outcomes
or mortality. These should be preferentially undertaken in dif-
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